# CALGB-10403: HCP commentary report > 41 HCP sources screened · 1065 verified claims from 28 sources · 13 findings. Updated 2026-10-08. ## Report - Trial: An Intergroup Phase II Clinical Trial for Adolescents and Young Adults With Untreated Acute Lymphoblastic Leukemia (ALL) - NCT ID: NCT00558519 - Registry: https://clinicaltrials.gov/study/NCT00558519 - Sponsor: Alliance for Clinical Trials in Oncology - Phase: Phase 2 - Status: Completed - Drugs: cyclophosphamide, dexamethasone - Indications: Leukemia - Version: v1.0.0, edition 1 - Accepted: 2026-10-08 - Last checked: 2026-10-08 - Release hash: 248afa050b6fd3a9af4e8672660f219a982be39d381bbd576c31b4cb02d8aef6 ## Counts - HCP commentary sources screened: 41 - Sources cited by verified claims: 28 - Verified claims: 1,065 - Findings: 13 - People found in screened sources: 47 - People identity-verified: 36 - Voices cited: 38 Counts describe the retained sources. They do not estimate how many HCPs hold a view. ## Abstract CALGB 10403 discussions ask how blinatumomab should fit into pediatric-inspired treatment for adolescents and young adults with newly diagnosed B-cell acute lymphoblastic leukemia. Other topics include residual-disease testing and timing, transplant in first remission, asparaginase reactions and exposure, age- and BMI-related dosing, CNS protection, relapse phenotype, treatment duration, and long-term follow-up. Discussions also address T-cell disease, administration logistics, drug and testing access, referral pathways, and patient support. The account draws on supplied podcasts, videos, and X threads. ## Open Medical Affairs question What evidence would clinicians need to integrate genotype, the depth and timing of MRD clearance, transplant harm and monitoring capability into a shared CR1 decision framework? ## Findings (titles) - F1. MRD-negative remission does not settle the CR1 transplant decision, particularly with adverse genetics - F2. Blinatumomab enthusiasm does not resolve which backbone to retain or how far to extrapolate E1910 - F3. MRD is discussed as an assay- and regimen-dependent trajectory, not a binary result - F4. Maintaining asparaginase exposure requires distinguishing reactions, inactivation and safe switching - F5. Exposure preservation has toxicity-specific limits: stopping, holding and rechallenging are not interchangeable - F6. Age, obesity and formulation drive dosing questions, but observational risk is not proof of a modifiable survival effect - F7. Adding blinatumomab is not the same CNS-risk question as replacing chemotherapy - F8. Manageable bispecific toxicity still requires expertise, delivery support and selective withholding - F9. Modified CALGB 10403 is described as feasible in Mexico and Guatemala, conditional on infrastructure and a learning curve - F10. Access and AYA support determine which evidence-based choices are real options - F11. Long-term CALGB 10403 discussion qualifies early optimism and keeps T-ALL distinct - F12. Earlier CD19 targeting raises a relapse-phenotype question, not an established frontline CD19-loss rate - F13. De-escalation, new delivery routes and CAR T are attractive, but their conditions remain explicit ## Sample findings ### F2. Blinatumomab enthusiasm does not resolve which backbone to retain or how far to extrapolate E1910 A podcast speaker asked how blinatumomab could be incorporated into pediatric-inspired therapy and whether adding it benefits patients with MRD undetectable by next-generation sequencing. Source: podcast, 2024-12-22. ### F12. Earlier CD19 targeting raises a relapse-phenotype question, not an established frontline CD19-loss rate An audience member in a podcast panel asked about the frequency of CD19-negative relapse after frontline blinatumomab consolidation given during MRD-negative remission. Source: podcast, 2026-01-14. ## Trial aspects | Aspect | Coverage | Claims | Sources | | --- | --- | ---: | ---: | | CR1 continuation versus transplant after pediatric induction | discussed | 39 | 5 | | Blinatumomab integration, alternative backbones, cycle number and maintenance | discussed | 34 | 8 | | MRD sensitivity, sampling, response kinetics and decision timing | discussed | 48 | 8 | | Asparaginase completion, reactions, silent inactivation and formulation switching | discussed | 39 | 3 | | Toxicity-specific reasons to continue, recover, rechallenge or discontinue | discussed | 34 | 3 | | Age and BMI selection, dosing adaptations and toxicity susceptibility | discussed | 43 | 7 | | CNS protection with add-on, substitution and early transplant sequences | discussed | 30 | 4 | | Bispecific safety, administration, routine-care exceptions and support | discussed | 36 | 6 | | Resource-adapted CALGB 10403 and the implementation learning curve | discussed | 29 | 3 | | Equity, sustainable testing, AYA services and referral capability | discussed | 37 | 4 | | Long-term durability, late events and T-ALL-specific uncertainties | discussed | 26 | 8 | | Relapse phenotype and treatment options after frontline CD19 exposure | discussed | 17 | 4 | | Conditional de-escalation, subcutaneous delivery and research consolidation | discussed | 47 | 10 | ## Cited sources by channel - Podcasts: 9 - X threads: 9 - YouTube: 10 ## Scope and limits This report does not judge efficacy, estimate HCP prevalence or consensus, give treatment advice. - Sources were found by searching for the trial's name, registry number and known aliases. Discussion that refers to the trial without naming it may be missing. - 20 points raised by the independent review are not yet resolved in this edition, such as a clinician view not yet captured as evidence or a qualifier to restore. The next refresh takes them up. - 3 further source limits are recorded in the machine-readable scope of this record. - The material is not a representative sample of HCPs or all public discussion. Multiple versions of the same conversation do not increase the number of independent clinical opinions. - Three indexed podcast sources could not be read. Searches focused on trial identifiers and registry aliases may miss unnamed references, acronym variants or different transcription renderings. - An unclear treatment name prevents attributing one CNS-progression observation to a specific regimen; it is not used to claim a blinatumomab-specific finding. - Full text was unavailable for two linked publications. Their abstracts provide context but cannot independently resolve every detailed study assertion made by speakers. - No separate protocol document was available beyond registry material, and regulatory material covered only part of the intervention-related records. Speaker claims about approvals or guidelines remain attributed claims, not independent regulatory conclusions. - Many discussions concern age extensions, LBL, Ph-positive alternatives, post-transplant monitoring or research consolidation. Those settings are not treated as results or universal rules for the original CALGB 10403 population. - Some source names or professional roles are incompletely established. Identity context does not identify an otherwise unnamed passage or give a view additional evidentiary weight. - Posting dates do not establish when a session occurred or show that a clinician changed position across settings. ## Offer - Size: Standard (28 commentary sources cited) - Current edition: $1,250. Buy it below; a purchase starts a check for new commentary and any newer edition follows at no charge - 3 months of weekly updates: $2,200 - 6 months of weekly updates: $3,100 - 12 months of weekly updates: $4,400 - Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (36 now), at most $1,250; people verified later in the term at no charge - Pricing: https://www.erudio.com/pricing - Buy now (card, through Stripe): https://www.erudio.com/reports/calgb-10403-nct00558519 - Agents: POST https://www.erudio.com/api/orders with {"report": "calgb-10403-nct00558519", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": ""}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your licence key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again - Talk to Tom and Audun (invoice, PO, questions): https://www.erudio.com/contact?report=calgb-10403-00558519 ## Cite Erudio Health. CALGB-10403 (NCT00558519): HCP commentary report. Edition 1, v1.0.0. Accepted 2026-10-08. https://www.erudio.com/reports/calgb-10403-nct00558519 ## Machine access - JSON: https://www.erudio.com/reports/calgb-10403-nct00558519.json - MCP: https://mcp.erudio.com/mcp, tool `get_report_card` with `{"slug": "calgb-10403-00558519"}`